Medical/Pharmaceuticals

SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...

2022-12-09 06:30 737

ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit

SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...

2022-12-08 23:00 1332

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...

2022-12-08 22:00 958

PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to participate in upcoming 41th Annual J.P. Morgan Healthcare ...

2022-12-08 21:00 614

Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers

* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses * Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refract...

2022-12-08 14:29 989

BSR KOREA Introduces "Wizbiosolutions Inc." as "2022 Global Procurement Marketer"

SEOUL, South Korea, Dec. 7, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...

2022-12-08 00:00 1511

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- TIANGEN, a high-tech biological enterprise, demonstrated its revolutionary nucleic acid extraction solution at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), fromDec 4 to...

2022-12-06 21:04 1303

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...

2022-12-06 21:01 1581

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...

2022-12-06 20:00 739

SK Biopharmaceuticals Wins Export Award for Cenobamate

SK Biopharmaceuticals receives the '$100 million Export Tower' award, becoming the first Korean pharmacompany to earn this prestige with a single innovative anti-seizure medication, cenobamate Cenobamate achieves over $100 million in exports in two years after launching in the U.S. andEurope – t...

2022-12-06 08:00 1122

Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors

YANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the appointments...

2022-12-05 22:33 1199

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the Acquisition of Dry Eye Disease...

2022-12-05 21:00 1422

Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company's MDMOOC platf...

2022-12-05 20:30 973

Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...

2022-12-05 20:00 948

The First IBCC Unveiled in Hainan

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) inHainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting. A patient-centered facility, the IBCC serves to improve inpatient experiences as well as medical s...

2022-12-05 15:55 782

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022

Poster session features a preliminary study result of potential seizure monitoring and detection for patients using SK Biopharmaceuticals' wearable device SK Biopharmaceuticals, Seoul National University Bundang Hospital plan to use Zero WiredTM to further pursue clinical research and develop it...

2022-12-05 08:00 747

Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022

JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies inChina that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study...

2022-12-04 17:00 1049

JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential

SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology. Presently, most cancer diagnosis is done through thinly sliced physic...

2022-12-03 09:58 1797

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...

2022-12-03 05:10 2918

Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus

SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus"...

2022-12-03 05:05 3166
12345 ... 145